News & Events about Personalis Inc.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT...
Business Wire
2 months ago
Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis NeXT Personal assay to evaluate...
Ticker Report
3 months ago
Shares of Personalis, Inc. (NASDAQ:PSNL Get Rating) have earned an average rating of Moderate Buy from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a ...
Business Wire
4 months ago
Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkersthose that integrate...
Business Wire
9 months ago
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the companys objective to accelerate expansion into the clinical...